Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2033

Conditions
Prostate Cancer MetastaticRadiation TherapyPositron-Emission Tomography
Interventions
RADIATION

stereotactic body radiotherapy

30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles

COMBINATION_PRODUCT

androgen deprivation therapy

Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer

RADIATION

Radiotherapy

RT to the prostate for de novo patients

Trial Locations (7)

90331

RECRUITING

Umeå University hospital, Umeå

Unknown

RECRUITING

Region Skåne, Lund

RECRUITING

Capio St Göran Hospital, Stockholm

RECRUITING

Södersjukhuset, Stockholm

RECRUITING

Karolinska University Hospital, Stockholm

RECRUITING

Ryhovs county hospital, Jönköping

RECRUITING

Region Örebro Län, Örebro

All Listed Sponsors
collaborator

University Hospital, Umeå

OTHER

collaborator

Karolinska University Hospital

OTHER

collaborator

Stockholm South General Hospital

OTHER

collaborator

Region Skane

OTHER

collaborator

Capio Sankt Görans Hospital

UNKNOWN

collaborator

Region Ã-rebro County

UNKNOWN

collaborator

Ryhov County Hospital

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

lead

Karin Soderkvist

OTHER